ECCB 2024

Sep 25, 2024

Scientific posters

ECCB 2024

Advancing Vaccine Development through Precise AI-driven Prediction of Protective Antigens.

ESMO 2024

Sep 16, 2024

Scientific posters

ESMO 2024

Phase 2 study of AI-designed personalized neoantigen cancer vaccine, EVX-01, in combination with pembrolizumab in advanced melanoma

ASCO 2024

Jun 4, 2024

Scientific posters

ASCO 2024

Immunogenicity of an AI-designed personalized neoantigen vaccine, EVX-01, in combination with anti-PD1 therapy in patients with metastatic melanoma